MDxHealth SA (MDXH) Stock Price & Analysis
MDxHealth SA (MDXH) closed at USD 0.6 on Thursday, October 15, 2026, down 4.45% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.63; the Oct 15, 2026 session ranged USD 0.58–0.65 on volume of 648,140 shares. Market capitalization is $57.59M, with a 52-week range of USD 0.4–5.33 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MDXH.md
Key facts (MDXH)
- Analysts: Buy (mean 2.33 on a 1–5 scale) (6 analysts), mean target USD 1.8 (range 1–3).
- Total return with dividends: 1Y -85.0% vs S&P 500 +18.1%; 5Y -95.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.09, revenue estimate $24.6M.
Analysts (MDXH)
Consensus Buy (mean 2.33 on a 1–5 scale), 6 analysts; mean target USD 1.8 (low 1, high 3).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-21 | BTIG | Target lowered | Buy | $4 → $2 |
| 2026-08-14 | Lake Street | Target lowered | Buy | $5 → $3 |
Total return (dividends reinvested) (MDXH)
| 1Y (from 2025-10-16) | 5Y (from 2021-11-01) | |
|---|---|---|
| Total return | -85.0% | -95.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -85.2% | -45.3% |
| Volatility (annualized) | 111.8% | 81.2% |
| Max drawdown | -92.0% (Oct 2025→Jun 2026) | -96.6% (Nov 2021→Jul 2026) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 0.6 |
|---|---|
| Change | ▼ 4.45% (down) |
| Previous Close | USD 0.63 |
| Open | USD 0.64 |
| Day Range | USD 0.58 – 0.65 |
| 52-Week Range | USD 0.4 – 5.33 |
| Volume | 648,140 shares |
| Market Cap | $57.59M |
| Exchange | NCM |
Technical Analysis (MDXH)
Nexqual's technical model rates MDXH "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.97 (neutral) |
| vs SMA50 | Below (USD 0.64) |
| MACD | -0.01 (negative) |
Analyst Ratings (MDXH)
Wall Street analysts rate MDXH "Buy" based on 6 analysts, with a mean price target of USD 1.8 (range USD 1–3), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 1.8 |
| High Target | USD 3 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 4 / 2 / 0 |
Earnings (MDXH)
| Next Earnings Date | 2026-11-12 |
|---|---|
| Revenue Estimate | $24.55M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.18 vs est -0.19 ▲ beat |
| 2026-03-31 | USD -0.17 vs est -0.15 ▼ miss |
| 2025-12-31 | USD -0.17 vs est -0.13 ▼ miss |
| 2025-09-30 | USD -0.16 vs est -0.11 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (MDXH)
| Total Revenue | $114.02M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +2.30% |
| Gross Margin | +62.86% |
| Operating Margin | -18.74% |
| Profit Margin | -32.74% |
| Current Ratio | 1.15 |
| Total Cash | $19.21M |
| Total Debt | $105.85M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (MDXH)
Nexqual rates MDxHealth SA's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 63%, operating -19% |
| Balance Sheet | Mixed — $19M cash vs $106M debt |
| Cash Flow | Weak — Operating cash flow -$5M (TTM) |
| Efficiency | Mixed — No data |
Ownership (MDXH)
| Insider Ownership | +22.14% |
|---|---|
| Institutional Ownership | +45.15% |
| Shares Outstanding | 95.42M |
| Float | 42.51M |
| Short % of Float | +1.62% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (MDXH)
MDxHealth SA is led by Michael K. McGarrity (age 62), CEO & Executive Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO & Executive Director | Michael K. McGarrity (age 62) |
|---|---|
| Interim Chief Financial Officer | Ron Kalfus (age 51) |
| Vice President of Finance & Accounting | Scott McMahan |
| Executive Vice President of Revenue Cycle Management | Kim Leroux |
Major Backers & Investors (MDXH)
Notable institutional backers of MDxHealth SA include Bleichroeder LP, MVM Partners, LLC, Perkins Capital Management, Inc., according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bleichroeder LP | 27.04% |
| MVM Partners, LLC | 17.23% |
| Perkins Capital Management, Inc. | 5.17% |
| Citadel | 1.87% |
| Jane Street Group, LLC | 1.84% |
| GSA Capital Partners LLP | 1.77% |
| Renaissance Technologies | 1.19% |
| Millennium Management | 0.84% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MYGN | Myriad Genetics, Inc. | USD 4.35 | ▲ 6.62% |
| FLGT | Fulgent Genetics, Inc. | USD 21.34 | ▲ 1.33% |
| CSTL | Castle Biosciences, Inc. | USD 33.8 | ▲ 2.8% |
| OPK | Opko Health, Inc. | USD 1.61 | ▲ 21.97% |
| FRNM | Freenome, Inc. | USD 12.29 | ▼ 2.81% |
| PSNL | Personalis, Inc. | USD 15.93 | ▲ 0.5% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt